This work was published in Nature Materials, entitled “A DNA nanodevice-based vaccine for cancer immunotherapy” （DOI：10.1038/s41563-020-0793-6, link to the paper: https://rdcu.be/b6SOx.）.
A major challenge in cancer vaccine therapy is the efficient delivery of antigens and adjuvants to stimulate a controlled yet robust tumor-specific T-cell response. Here, the researchers described a structurally well defined DNA nanodevice vaccine. It is generated by precisely assembling two types of molecular adjuvants and an antigen peptide within the inner cavity of a tubular DNA nanostructure. The DNA nanodevice vaccine can be activated in the subcellular environment to trigger T-cell activation and cancer cytotoxicity. The integration of low pH-responsive DNA ‘locking strands’ outside the nanostructures enables the opening of the vaccine in lysosomes in antigen-presenting cells, exposing adjuvants and antigens to activate a strong immune response.
The DNA nanodevice vaccine elicited a potent antigen-specific T-cell response, with subsequent tumor regression in mouse cancer models. Nanodevice vaccination generated long-term T-cell responses that potently protected the mice against tumor rechallenge.
This work was supported by the Beijing Municipal Science & Technology Commission, the National Basic Research Program of China, the National Natural Science Foundation of China, the Science Fund for Creative Research Groups of the National Natural Science Foundation of China, the Key Research Program of Frontier Sciences, CAS, the CAS Interdisciplinary Innovation Team and K. C. Wong Education Foundation and the Strategic Priority Research Program of Chinese Academy of Sciences.
Figure. Design and characterization of the antigen/adjuvant-functionalized DNA nanodevice vaccine